Delving into the Latest Updates on Cesa Projects International with Synapse

Overview

This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection.
Primary endpoint: significant drop in viral load AV2-DM versus placebo
Secondary endpoint:the number of patients with adverse events

Start Date01 Aug 2012

Sponsor / Collaborator

Cesa Projects International

100 Clinical Results associated with Cesa Projects International

Login to view more data

0 Patents (Medical) associated with Cesa Projects International

Login to view more data

100 Deals associated with Cesa Projects International

Login to view more data

100 Translational Medicine associated with Cesa Projects International

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data